Flec-SL – AFNET 3 Trial

Title

Short-term pharmacological reversal of atrial fibrillation

Summary

Targeted pharmacological reversal of electrical remodeling after cardioversion of atrial fibrillation; randomized controlled clinical trial

Coordinating Investigator

Prof. Paulus Kirchhof, Birmingham, UK / Münster, Germany

Overall Responsibility

Atrial Fibrillation NETwork (AFNET), Münster, Germany

Registration

http://www.controlled-trials.com/ISRCTN62728743 
http://clinicaltrials.gov/show/NCT00215774

Current Status

Completed

Funding

German Federal Ministry of Education and Research

Publications

Oto E, Okutucu S, Katircioglu-Öztürk D, Altay Güvenir H, Karaagaoglu E, Borggrefe M, Breithardt G, Goette A, Ravens U, Steinbeck G, Wegscheider K, Oto A, Kirchhof P. Predictors of sinus rhythm after electrical cardioversion of atrial fibrillation: results from a data mining project on the Flec-SL trial data set. Europace. 2017 Jun 1; 19 (6):921 - 928. pii: euw144. doi: 10.1093/europace/euw144 . Epub 2016 Jul 2

Apostolakis S, Haeusler KG, Oeff M, Treszl A, Andresen D, Borggrefe M, Lip GY, Meinertz T, Parade U, Samol A, Steinbeck G, Wegscheider K, Breithardt G, Kirchhof P. Low stroke risk after elective cardioversion of atrial fibrillation: An analysis of the Flec-SL trial. Int J Cardiol. 2013 Jul 17. doi: 10.1016/j.ijcard.2013.06.090

Kirchhof P et al: Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. Lancet 18.06.2012, doi:10.1016/S0140-6736(12)60570-4